Format

Send to

Choose Destination
Front Immunol. 2018 Jun 28;9:1480. doi: 10.3389/fimmu.2018.01480. eCollection 2018.

Hepatitis C Vaccines, Antibodies, and T Cells.

Author information

1
Centre de Recherche du Centre hospitalier de l'Université de Montréal (CRCHUM), Montréal, QC, Canada.
2
Département de médecine, Faculté de médecine, Université de Montréal, Montréal, QC, Canada.

Abstract

The development of vaccines that protect against persistent hepatitis C virus (HCV) infection remain a public health priority. The broad use of highly effective direct-acting antivirals (DAAs) is unlikely to achieve HCV elimination without vaccines that can limit viral transmission. Two vaccines targeting either the antibody or the T cell response are currently in preclinical or clinical trials. Next-generation vaccines will likely involve a combination of these two strategies. This review summarizes the state of knowledge about the immune protective role of HCV-specific antibodies and T cells and the current vaccine strategies. In addition, it discusses the potential efficacy of vaccination in DAA-cured individuals. Finally, it summarizes the challenges to vaccine development and the collaborative efforts required to overcome them.

KEYWORDS:

T cells; antibodies; hepatitis C; reinfection; vaccines

Supplemental Content

Full text links

Icon for Frontiers Media SA Icon for PubMed Central
Loading ...
Support Center